Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 9/20 | 0.62 |
| ▸ | ECE1 | P42892 | 5/20 | 0.58 |
| ▸ | IL1RN | P18510 | 9/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.57 |
| ▸ | EDNRA | P25101 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31720355 | 0.95 | ECE1 (0.59) | ERAP2ECE1IL1RNERAP1EDNRA | |
| SCHEMBL30465906 | 0.94 | ERAP2 (0.62) | ERAP2ECE1IL1RNERAP1EDNRA | |
| SCHEMBL31720553 | 0.92 | ERAP2 (0.63) | ERAP2ECE1IL1RNERAP1EDNRA | |
| SCHEMBL30102898 | 0.91 | ERAP2 (0.61) | ERAP2ECE1IL1RNERAP1EDNRA | |
| SCHEMBL30465848 | 0.91 | ERAP2 (0.71) | ERAP2ECE1IL1RNERAP1EDNRA | |
| SCHEMBL30465916 | 0.90 | ERAP2 (0.64) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL30544315 | 0.90 | KISS1R (0.60) | ERAP2ECE1IL1RNERAP1EDNRA | |
| SCHEMBL32667969 | 0.90 | ERAP2 (0.60) | ERAP2ECE1IL1RNERAP1EDNRA | |
| SCHEMBL30465911 | 0.90 | ECE1 (0.59) | ERAP2ECE1IL1RNERAP1EDNRA | |
| SCHEMBL30465868 | 0.90 | ECE1 (0.59) | ERAP2ECE1IL1RNERAP1EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | claimed |
| EP-4448544-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-10-23 | — | — | EP | claimed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | claimed |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4448544-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | ERAP2 257/4885ECE1 1288/4885IL1RN 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.